Original articleSystematic reviews and meta-analysesCancer Risk After Resection of Polypoid Dysplasia in Patients With Longstanding Ulcerative Colitis: A Meta-analysis
Section snippets
Methods
The aim of this meta-analysis was to determine the rate of development of CRC in patients with longstanding ulcerative colitis who have had a polypoid dysplastic lesion resected and subsequently undergone colonoscopic surveillance.
Results
From the initial keyword search, 425 articles were selected and 1 Cochrane review. The Cochrane review did not contain any includable data not obtained from the original articles. Of the 425 head titles, 265 articles were selected. A second selection was made on abstract content, where 49 articles were further reviewed. These selected articles were scrutinized in depth. Forty-two studies did not meet the predefined inclusion or exclusion criteria. Finally, 7 articles were selected. From these
Discussion
This is a meta-analysis on CRC risk after resection of polypoid dysplasia in longstanding IBD. A total of 2.4% of patients developed CRC after an average follow-up of 54 months. The pooled CRC rate was 5.3 occurrences per 1000 patient years of follow-up from 10 studies including 376 patients and 1706 years of patient follow-up. The rate for any advanced lesion was 7 per 1000 patient years of follow-up, and the rate for any dysplasia was 65 occurrences per 1000 patient years. There was no
Acknowledgments
Data from this study were presented as an oral presentation on October 22 at United European Gastroenterology Week 2012, Amsterdam, and accepted for oral presentation on May 21 at Digestive Disease Week 2013, Orlando.
References (43)
- et al.
Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010
Gastroenterology
(2012) - et al.
Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies
Clin Gastroenterol Hepatol
(2012) - et al.
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
Gastroenterology
(2004) - et al.
Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis
Gastroenterology
(2003) - et al.
Cancer surveillance in ulcerative colitis: experience over 15 years
Lancet
(1983) - et al.
The differentiation of true adenomas from colitis-associated dysplasia in ulcerative colitis: a comparative immunohistochemical study
Hum Pathol
(1999) - et al.
Variability in the diagnosis and management of adenoma-like and non-adenoma-like dysplasia associated lesions or masses in inflammatory bowel disease: an internet-based study
Gastrointest Endosc
(2007) - et al.
Most dysplasia in ulcerative colitis is visible at colonoscopy
Gastrointest Endosc
(2004) - et al.
Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps
Gastroenterology
(1999) - et al.
Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location
Gastrointest Endosc
(2011)
Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis
Clin Gastroenterol Hepatol
Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis
Gastroenterology
Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005
Gastroenterology
Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease
Gastroenterology
The risk of colorectal cancer in ulcerative colitis: a meta-analysis
Gut
Ulcerative colitis and colorectal cancer: a population-based study
N Engl J Med
Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years
Gastroenterology
Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease
Aliment Pharmacol Ther
Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study
Inflamm Bowel Dis
Dysplasia and carcinoma in longstanding ulcerative colitis: an endoscopic and histological surveillance programme
Gut
ALMs versus DALMs in ulcerative colitis: polypectomy or colectomy?
Gastroenterology
Cited by (0)
Conflicts of interest These authors disclose the following: Evelien Dekker received research funding and equipment on loan from Olympus. Simon P. L. Travis received consulting fees from Abbott, Asahi-Kasei, Bristol-Myers Squibb, Cosmo Technologies, Coronado Biosciences, Ferring Pharmaceuticals, Genentech, Genzyme Corp, GlaxoSmithKline, Janssen, Lexicon Pharmaceuticals, Merck Research Laboratories, Millennium Pharmaceuticals, Nisshin Kyorin Pharmaceuticals, Novartis, Novo Nordisk, NPS Pharmaceuticals, PDL Biopharma, Pfizer, Procter and Gamble, Santarus, Schering Plough, Shire Pharmaceuticals, Sigmoid Pharma Ltd, Tillotts Pharma AG, TxCell SA, UCB Pharma, and Warner Chilcott UK Ltd; research grants from Abbott, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Procter and Gamble, Shire Pharmaceuticals, and UCB Pharma; payments for lectures/speakers bureaus from Abbott, Janssen, Ferring Pharmaceuticals, and Warner Chilcott; and holds no stock/stock options. James E. East is on the Advisory board at Cosmo Pharmaceuticals and is a speaker for Abbott Laboratories. The remaining authors disclose no conflicts.